secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001104659-22-117179
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics reports Q3 net loss $0.7M; FDA meeting on IV Tramadol and acquisition of Baergic Bio
--------------------------------------------------------------------------------

- Q3 2022 net loss $0.7M ($0.45/share) vs $0.9M ($0.79/share) in Q3 2021.
- Cash $0.2M at Sep 30, 2022 (down from $3.8M at Dec 31, 2021); then raised ~$10.4M net in October offering.
- FDA agreed proposed IV Tramadol study design appears reasonable; detailed protocol submission planned.
- Completed acquisition of Baergic Bio, adding BAER-101 (GABA-A α2/3 PAM) for refractory epilepsies and panic disorders.
- Effected 1-for-15 reverse stock split and closed $12M public offering; regained Nasdaq compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922117179/0001104659-22-117179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922117179/tm2230162d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer